Skip to main content

Lupus

      RT @KDAO2011: #ACR20 Dr. M. Crow on Lupus #StateofArtLecture reviews treatment of SLE:
      1. HCQ is the foundation of Rx
      2
      4 years ago
      #ACR20 Dr. M. Crow on Lupus #StateofArtLecture reviews treatment of SLE: 1. HCQ is the foundation of Rx 2. keep pred <7.5mg/day 3. belimumab works better when given early in disease (<2 yrs) 4. combination Rx may be needed @rheumnow https://t.co/6zh1xkLXgN
      Saturday was the day 2 with many posters and live sessions at the 2020 Virtual ACR/ARP meeting. Here are a few of my highlights from day two: Targeting Plasmacytoid Dendritic Cells in Lupus…
      RT @lexmeara: So much more work to be done- the traditional tools for estimating CVD in rheumatic patients are likely no
      4 years ago
      So much more work to be done- the traditional tools for estimating CVD in rheumatic patients are likely not accurate especially patients with SLE- abstract 1286 @RheumNow #acr20 https://t.co/L6Z1fsO2he
      RT @RichardPAConway: Dr @AliDuarteMD presents on incidence of SLE over last 40 years, 29% increase overall, and doubled
      Dr @AliDuarteMD presents on incidence of SLE over last 40 years, 29% increase overall, and doubled in males. Overall cyclical pattern. Abstr#1024 #ACR20 @rheumnow https://t.co/SSVY0U0SIg
      HCQ and QTc in RA and SLE Patients: Dr. Kathryn Dao

      Dr. Kathryn Dao reviews abstract #0431 presented at the 2020 ACR annual meeting. 

      RT @bella_mehta: Another addition to "Where you live matters!" NYC principal component analysis of 140 neighborhood char
      4 years ago
      Another addition to "Where you live matters!" NYC principal component analysis of 140 neighborhood characteristics show - location and SES influence incidence and severity of #COVID19 in #SLE @rheumnow #ACR20 ABS#0984
      RT @drpnash: Toll-like Receptor Inhibitor Peptide Improves the Clinical, Immunologic, and Pathologic Manifestations of S
      4 years ago
      Toll-like Receptor Inhibitor Peptide Improves the Clinical, Immunologic, and Pathologic Manifestations of Systemic Lupus Erythematosus https://t.co/hAqngljp2b #sle #tollreceptorinhib TLR inhib in mice for SLE
      RT @DrPedsRheum: TMA and SLE by Dr Levy @SickKidsNews

      👉TMA triad - microangiopathic hemolytic anemia, thrombocytopen
      4 years ago
      TMA and SLE by Dr Levy @SickKidsNews 👉TMA triad - microangiopathic hemolytic anemia, thrombocytopenia, impaired renal function 👉TTP pentad - fever, thrombocytopenia, hemolytic anemia, renal impairment, neurologic involvement #ACR20 #ACRambassador https://t.co/xnO1JkhSFT
      RT @DrMiniDey: Neighbourhood characteristics &amp; socioeconomic factors important not only for contracting #COVID19 but
      4 years ago
      Neighbourhood characteristics & socioeconomic factors important not only for contracting #COVID19 but also severe infection in #SLE. Results useful for developing strategies to address socioeconomic stressors in this population. Abs#0984 #ACR20 @RheumNow https://t.co/u4YDcfEcSQ
      RT @DrMiniDey: Time-trend analysis in hospitalised #infection in #lupus
      -Incr. rate of hospitalised infections over time
      4 years ago
      Time-trend analysis in hospitalised #infection in #lupus -Incr. rate of hospitalised infections over time -#Sepsis surpassed #pneumonia as most common hospitalised infection in 2011-12; twice as many sepsis vs pneumonia by 2015-16 Abs#0980 #ACR20 @RheumNow https://t.co/M8xbMDFUTS https://t.co/ShogvxbhzN